Siren L.L.C. Lowers Stock Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Siren L.L.C. lowered its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 73.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 1,053,464 shares of the company’s stock after selling 2,974,053 shares during the period. Centessa Pharmaceuticals comprises approximately 1.2% of Siren L.L.C.’s holdings, making the stock its 23rd largest position. Siren L.L.C. owned 0.71% of Centessa Pharmaceuticals worth $41,844,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of CNTA. Millennium Management LLC lifted its position in shares of Centessa Pharmaceuticals by 52.9% in the first quarter. Millennium Management LLC now owns 609,188 shares of the company’s stock valued at $8,760,000 after acquiring an additional 210,737 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Centessa Pharmaceuticals during the first quarter worth about $2,176,000. Geode Capital Management LLC raised its stake in Centessa Pharmaceuticals by 44.7% during the 2nd quarter. Geode Capital Management LLC now owns 87,435 shares of the company’s stock valued at $1,149,000 after purchasing an additional 26,994 shares during the period. JPMorgan Chase & Co. raised its stake in Centessa Pharmaceuticals by 155.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 428,434 shares of the company’s stock valued at $5,630,000 after purchasing an additional 260,702 shares during the period. Finally, Legal & General Group Plc lifted its holdings in Centessa Pharmaceuticals by 29.2% in the 2nd quarter. Legal & General Group Plc now owns 98,256 shares of the company’s stock worth $1,291,000 after purchasing an additional 22,205 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Lifesci Capital lowered shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 1st. Guggenheim downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 2nd. B. Riley Financial lowered shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Needham & Company LLC cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, Wolfe Research downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a report on Tuesday, March 31st. Four analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $41.33.

Centessa Pharmaceuticals Price Performance

Shares of Centessa Pharmaceuticals stock opened at $40.50 on Friday. The firm has a market cap of $6.27 billion, a PE ratio of -22.63 and a beta of 1.11. The stock has a 50 day moving average of $40.12 and a 200 day moving average of $33.64. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $12.74 and a 12 month high of $40.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). On average, research analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.